Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

NCT00238121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Recurrent Uterine Sarcoma
Stage III Uterine Sarcoma
Stage IV Uterine Sarcoma
Uterine Carcinosarcoma

Interventions

DRUG: sorafenib tosylate

Sponsor

National Cancer Institute (NCI)